Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination penicillin-class antibacterial agent and a beta-lactamase inhibitor. It is active against a broad spectrum of gram-positive and gram-negative bacteria, including *Pseudomonas aeruginosa*.
## Primary Indications
Treatment of moderate to severe infections caused by susceptible bacteria, including:
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (in combination with an aminoglycoside)
## Adult Dosing
* **Standard Dose:** 3.375 grams every 6 hours (piperacillin 3g / tazobactam 0.375g) or 4.5 grams every 6 hours (piperacillin 4g / tazobactam 0.5g).
* **Dosing for *Pseudomonas aeruginosa* or other resistant organisms:** 4.5 grams every 6 or 8 hours may be required depending on local susceptibility patterns and severity of infection.
* **Maximum Dose:** Not explicitly defined, but prolonged or higher frequency dosing may be used in specific severe infections. Generally, 4.5 grams every 6 hours is common.
## Pediatric Dosing
* **Children 2 months and older:** Dosing is based on piperacillin content.
* **Intra-abdominal infections:** 100 mg piperacillin/kg/dose every 8 hours. Maximum dose 4 g/dose.
* **Complicated skin and skin structure infections:** 75 mg piperacillin/kg/dose every 6 hours. Maximum dose 4 g/dose.
* **Febrile neutropenia:** Dosing varies based on specific guidelines, often 100 mg piperacillin/kg/dose every 8 hours, or 300 mg piperacillin/kg/day divided every 6 or 8 hours, in combination with an aminoglycoside.
* **Note:** Maximum dose of tazobactam is 0.5 g per dose when calculated by piperacillin weight-based dosing.
## Dose Adjustments
* **Renal Impairment (CrCl < 40 mL/min):**
* 3.375 g every 8 hours
* 4.5 g every 8-12 hours (depending on severity and specific agent)
* **CrCl < 20 mL/min:** 2.25 g every 8 hours, or 4.5 g every 12 hours.
* **Hepatic Impairment:** No dose adjustment generally recommended, but caution is advised.
* **Hemodialysis:** Administer dose after hemodialysis and supplement every dialysis period.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillin, or any component of the formulation.
* History of a severe allergic reaction (e.g., anaphylaxis) to a beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, hypokalemia.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe allergic reactions (anaphylaxis), seizures, interstitial nephritis, Stevens-Johnson syndrome/toxic epidermal necrolysis.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations.
* **Aminoglycosides:** May have synergistic or antagonistic effects depending on the specific organisms and pathogens. Co-administration is common for severe infections like febrile neutropenia, but separate administration is recommended.
* **Neuromuscular blocking agents:** Penicillins can prolong the action of neuromuscular blocking agents.
* **Warfarin:** Penicillins may decrease serum concentrations of warfarin. Monitor INR closely.
* **Methotrexate:** Penicillins can decrease methotrexate clearance, increasing toxicity.
## Monitoring
* **Renal function:** Especially in patients with pre-existing renal impairment or those receiving nephrotoxic agents.
* **Electrolytes:** Particularly potassium levels.
* **Signs and symptoms of infection:** Clinical response, fever, white blood cell count.
* **Signs and symptoms of hypersensitivity reactions.**
* **Bowel function:** For diarrhea, especially if severe or persistent, to rule out *C. difficile*.
## Clinical Pearls
* Piperacillin/tazobactam covers *Pseudomonas aeruginosa*, which is a key advantage in treating hospital-acquired infections.
* The tazobactam component extends the spectrum of activity to include many beta-lactamase producing organisms.
* Reconstituted solution stability is limited; follow manufacturer guidelines for storage.
* Dosing in critically ill patients may require consideration of pharmacokinetic/pharmacodynamic principles, including continuous infusions or higher doses, depending on local protocols.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical judgment. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.
